Ad Scientiam SAS

Based in France, Ad Scientiam specializes in developing digital biomarkers that improve the management of severe diseases, utilizing advanced technology for real-time patient assessment and data analytics via mobile platforms. Ad Scientiam, founded in 2013 in Paris, France, focuses on digital health technologies. In October 2025, Ad Scientiam raised EUR 5 million of venture funding from new investor TechLife Capital. As part of the transaction, TechLife Capital will hold majority stake.

Ad Scientiam specializes in the development and implementation of digital biomarkers aimed at enhancing the management of severe and debilitating diseases. Their core product, MSCopilot®, is the first medical software device specifically designed for the real-time self-assessment of patients with Multiple Sclerosis (MS). Launched in 2018, MSCopilot® utilizes patients' smartphones to continuously capture over 350 digital biomarkers related to physiological and behavioral characteristics, thereby objectively assessing the symptoms of MS. The digital biomarkers they create provide healthcare professionals with precise data regarding patient symptoms and experiences, which facilitates more personalized and efficient care.

Ad Scientiam's solutions primarily target healthcare providers, researchers, and patients, with a focus on markets across Europe and North America, aiming to improve care outcomes and expedite treatment development. Ad Scientiam's revenue generation is anchored in the provision of its digital biomarker solutions, specifically through business-to-business (B2B) transactions with healthcare providers and research institutions. The company's flagship product, MSCopilot®, is offered under a partnership model, where healthcare entities subscribe to the service for continuous patient monitoring and data collection. This transactional structure enables clients to implement the MSCopilot® system for a defined subscription period, granting access to the associated digital tools and analytics.

Additionally, Ad Scientiam engages in collaborations with pharmaceutical companies for joint research initiatives, thus broadening its revenue avenues while maintaining a focus on delivering innovative healthcare solutions. In October 2025, Ad Scientiam raised EUR 0. 54 mn in venture funding from new investor TechLife Capital. The company will use this funding to expand its portfolio of digital biomarkers and medical software, enter new therapeutic areas, and strengthen commercialization models across the drug lifecycle.